Seattle-based healthcare PE firm with $11B+ raised, investing $20M-$150M in middle-market healthcare services and life sciences companies. Growth Buyout fund covers services; Life Sciences fund covers therapeutics.
Auto-detected from Frazier Healthcare Partners's website.
Healthcare-focused investor at Frazier since 2006, previously at Morgan Stanley Capital Partners and Investment Banking.
General Partner at Frazier since 2003, leads Growth Buyout team's debt capital markets activities.
General Partner at Frazier since 2019, previously Principal at Norwest Equity Partners for 10+ years.
Principal at Frazier since 2019, previously at McKinsey, Credit Suisse, and Morgan Stanley.
Principal at Frazier since 2019, previously investment banking analyst at Robert W Baird.
Partner at Frazier since 2016, previously at The Edgewater Funds and CIVC Partners.
Led Frazier's Buyout team since 1995, scaling from four to over 100 members and raising $11B+ in capital.
Cardiologist and healthcare investor at Frazier since 1999, former Associate Professor at University of Washington.
General Partner and New York office leader at Frazier since 2012, previously at RBC Capital Markets.
General Partner at Frazier since 2016, previously at Kohlberg & Company focusing on healthcare investments.
Principal at Frazier since 2016, previously healthcare investment banking analyst at Harris Williams & Co.
Focus and check size from the firm's website. Website reachable as of Aug 2026.
A fit check scores your pitch against their thesis, stage and ticket. An email draft uses their real deals and thesis, not a template.